Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
3149 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Breast Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape. Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively. Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Breast Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Breast Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Breast Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 19 Breast Cancer Overview 20 Therapeutics Development 21 Breast Cancer - Therapeutics under Development by Companies 23 Breast Cancer - Therapeutics under Investigation by Universities/Institutes 66 Breast Cancer - Pipeline Products Glance 75 Breast Cancer - Products under Development by Companies 79 Breast Cancer - Products under Investigation by Universities/Institutes 145 Breast Cancer - Companies Involved in Therapeutics Development 160 Breast Cancer - Therapeutics Assessment 617 Drug Profiles 713 Breast Cancer - Dormant Projects 2934 Breast Cancer - Discontinued Products 3000 Breast Cancer - Product Development Milestones 3013 Appendix 3027
List of Tables
Number of Products under Development for Breast Cancer, H2 2016 142 Number of Products under Development for Breast Cancer - Comparative Analysis, H2 2016 143 Number of Products under Development by Companies, H2 2016 145 Number of Products under Development by Companies, H2 2016 (Contd..1) 146 Number of Products under Development by Companies, H2 2016 (Contd..2) 147 Number of Products under Development by Companies, H2 2016 (Contd..3) 148 Number of Products under Development by Companies, H2 2016 (Contd..4) 149 Number of Products under Development by Companies, H2 2016 (Contd..5) 150 Number of Products under Development by Companies, H2 2016 (Contd..6) 151 Number of Products under Development by Companies, H2 2016 (Contd..7) 152 Number of Products under Development by Companies, H2 2016 (Contd..8) 153 Number of Products under Development by Companies, H2 2016 (Contd..9) 154 Number of Products under Development by Companies, H2 2016 (Contd..10) 155 Number of Products under Development by Companies, H2 2016 (Contd..11) 156 Number of Products under Development by Companies, H2 2016 (Contd..12) 157 Number of Products under Development by Companies, H2 2016 (Contd..13) 158 Number of Products under Development by Companies, H2 2016 (Contd..14) 159 Number of Products under Development by Companies, H2 2016 (Contd..15) 160 Number of Products under Development by Companies, H2 2016 (Contd..16) 161 Number of Products under Development by Companies, H2 2016 (Contd..17) 162 Number of Products under Development by Companies, H2 2016 (Contd..18) 163 Number of Products under Development by Companies, H2 2016 (Contd..19) 164 Number of Products under Development by Companies, H2 2016 (Contd..20) 165 Number of Products under Development by Companies, H2 2016 (Contd..21) 166 Number of Products under Development by Companies, H2 2016 (Contd..22) 167 Number of Products under Development by Companies, H2 2016 (Contd..23) 168 Number of Products under Development by Companies, H2 2016 (Contd..24) 169 Number of Products under Development by Companies, H2 2016 (Contd..25) 170 Number of Products under Development by Companies, H2 2016 (Contd..26) 171 Number of Products under Development by Companies, H2 2016 (Contd..27) 172 Number of Products under Development by Companies, H2 2016 (Contd..28) 173 Number of Products under Development by Companies, H2 2016 (Contd..29) 174 Number of Products under Development by Companies, H2 2016 (Contd..30) 175 Number of Products under Development by Companies, H2 2016 (Contd..31) 176 Number of Products under Development by Companies, H2 2016 (Contd..32) 177 Number of Products under Development by Companies, H2 2016 (Contd..33) 178 Number of Products under Development by Companies, H2 2016 (Contd..34) 179 Number of Products under Development by Companies, H2 2016 (Contd..35) 180 Number of Products under Development by Companies, H2 2016 (Contd..36) 181 Number of Products under Development by Companies, H2 2016 (Contd..37) 182 Number of Products under Development by Companies, H2 2016 (Contd..38) 183 Number of Products under Development by Companies, H2 2016 (Contd..39) 184 Number of Products under Development by Companies, H2 2016 (Contd..40) 185 Number of Products under Development by Companies, H2 2016 (Contd..41) 186 Number of Products under Investigation by Universities/Institutes, H2 2016 187 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 188 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 189 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 190 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 191 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 192 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 193 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 194 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 195 Comparative Analysis by Late Stage Development, H2 2016 196 Comparative Analysis by Clinical Stage Development, H2 2016 197 Comparative Analysis by Early Stage Development, H2 2016 198 Comparative Analysis by Unknown Stage Development, H2 2016 199 Products under Development by Companies, H2 2016 200 Products under Development by Companies, H2 2016 (Contd..1) 201 Products under Development by Companies, H2 2016 (Contd..2) 202 Products under Development by Companies, H2 2016 (Contd..3) 203 Products under Development by Companies, H2 2016 (Contd..4) 204 Products under Development by Companies, H2 2016 (Contd..5) 205 Products under Development by Companies, H2 2016 (Contd..6) 206 Products under Development by Companies, H2 2016 (Contd..7) 207 Products under Development by Companies, H2 2016 (Contd..8) 208 Products under Development by Companies, H2 2016 (Contd..9) 209 Products under Development by Companies, H2 2016 (Contd..10) 210 Products under Development by Companies, H2 2016 (Contd..11) 211 Products under Development by Companies, H2 2016 (Contd..12) 212 Products under Development by Companies, H2 2016 (Contd..13) 213 Products under Development by Companies, H2 2016 (Contd..14) 214 Products under Development by Companies, H2 2016 (Contd..15) 215 Products under Development by Companies, H2 2016 (Contd..16) 216 Products under Development by Companies, H2 2016 (Contd..17) 217 Products under Development by Companies, H2 2016 (Contd..18) 218 Products under Development by Companies, H2 2016 (Contd..19) 219 Products under Development by Companies, H2 2016 (Contd..20) 220 Products under Development by Companies, H2 2016 (Contd..21) 221 Products under Development by Companies, H2 2016 (Contd..22) 222 Products under Development by Companies, H2 2016 (Contd..23) 223 Products under Development by Companies, H2 2016 (Contd..24) 224 Products under Development by Companies, H2 2016 (Contd..25) 225 Products under Development by Companies, H2 2016 (Contd..26) 226 Products under Development by Companies, H2 2016 (Contd..27) 227 Products under Development by Companies, H2 2016 (Contd..28) 228 Products under Development by Companies, H2 2016 (Contd..29) 229 Products under Development by Companies, H2 2016 (Contd..30) 230 Products under Development by Companies, H2 2016 (Contd..31) 231 Products under Development by Companies, H2 2016 (Contd..32) 232 Products under Development by Companies, H2 2016 (Contd..33) 233 Products under Development by Companies, H2 2016 (Contd..34) 234 Products under Development by Companies, H2 2016 (Contd..35) 235 Products under Development by Companies, H2 2016 (Contd..36) 236 Products under Development by Companies, H2 2016 (Contd..37) 237 Products under Development by Companies, H2 2016 (Contd..38) 238 Products under Development by Companies, H2 2016 (Contd..39) 239 Products under Development by Companies, H2 2016 (Contd..40) 240 Products under Development by Companies, H2 2016 (Contd..41) 241 Products under Development by Companies, H2 2016 (Contd..42) 242 Products under Development by Companies, H2 2016 (Contd..43) 243 Products under Development by Companies, H2 2016 (Contd..44) 244 Products under Development by Companies, H2 2016 (Contd..45) 245 Products under Development by Companies, H2 2016 (Contd..46) 246 Products under Development by Companies, H2 2016 (Contd..47) 247 Products under Development by Companies, H2 2016 (Contd..48) 248 Products under Development by Companies, H2 2016 (Contd..49) 249 Products under Development by Companies, H2 2016 (Contd..50) 250 Products under Development by Companies, H2 2016 (Contd..51) 251 Products under Development by Companies, H2 2016 (Contd..52) 252 Products under Development by Companies, H2 2016 (Contd..53) 253 Products under Development by Companies, H2 2016 (Contd..54) 254 Products under Development by Companies, H2 2016 (Contd..55) 255 Products under Development by Companies, H2 2016 (Contd..56) 256 Products under Development by Companies, H2 2016 (Contd..57) 257 Products under Development by Companies, H2 2016 (Contd..58) 258 Products under Development by Companies, H2 2016 (Contd..59) 259 Products under Development by Companies, H2 2016 (Contd..60) 260 Products under Development by Companies, H2 2016 (Contd..61) 261 Products under Development by Companies, H2 2016 (Contd..62) 262 Products under Development by Companies, H2 2016 (Contd..63) 263 Products under Development by Companies, H2 2016 (Contd..64) 264 Products under Development by Companies, H2 2016 (Contd..65) 265 Products under Investigation by Universities/Institutes, H2 2016 266 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 267 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 268 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 269 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 270 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 271 Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 272 Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 273 Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 274 Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 275 Products under Investigation by Universities/Institutes, H2 2016 (Contd..10) 276 Products under Investigation by Universities/Institutes, H2 2016 (Contd..11) 277 Products under Investigation by Universities/Institutes, H2 2016 (Contd..12) 278 Products under Investigation by Universities/Institutes, H2 2016 (Contd..13) 279 Products under Investigation by Universities/Institutes, H2 2016 (Contd..14) 280 Breast Cancer - Pipeline by 3-D Matrix Ltd, H2 2016 281 Breast Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 282 Breast Cancer - Pipeline by 3SBio Inc, H2 2016 283 Breast Cancer - Pipeline by 4SC AG, H2 2016 284 Breast Cancer - Pipeline by A&G Pharmaceutical Inc, H2 2016 285 Breast Cancer - Pipeline by AB Science SA, H2 2016 286 Breast Cancer - Pipeline by AbbVie Inc, H2 2016 287 Breast Cancer - Pipeline by AbGenomics International Inc, H2 2016 288 Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 289 Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 290 Breast Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 291 Breast Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 292 Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 293 Breast Cancer - Pipeline by Aduro BioTech Inc, H2 2016 294 Breast Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 295 Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 296 Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 297 Breast Cancer - Pipeline by Advantagene Inc, H2 2016 298 Breast Cancer - Pipeline by Advaxis Inc, H2 2016 299 Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 300 Breast Cancer - Pipeline by Aegis Therapeutics LLC, H2 2016 301 Breast Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 302 Breast Cancer - Pipeline by Aerpio Therapeutics Inc, H2 2016 303 Breast Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 304 Breast Cancer - Pipeline by Affichem SA, H2 2016 305 Breast Cancer - Pipeline by Agenus Inc, H2 2016 306 Breast Cancer - Pipeline by Agilvax Inc, H2 2016 307 Breast Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016 308 Breast Cancer - Pipeline by Alchemia Ltd, H2 2016 309 Breast Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 310 Breast Cancer - Pipeline by Alissa Pharma, H2 2016 311 Breast Cancer - Pipeline by Almac Discovery Ltd, H2 2016 312 Breast Cancer - Pipeline by Alteogen Inc, H2 2016 313 Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016 314 Breast Cancer - Pipeline by Ambrx Inc, H2 2016 315 Breast Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 316 Breast Cancer - Pipeline by Amgen Inc, H2 2016 317 Breast Cancer - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 318 Breast Cancer - Pipeline by Amplyx Pharmaceuticals Inc, H2 2016 319 Breast Cancer - Pipeline by Angion Biomedica Corp, H2 2016 320 Breast Cancer - Pipeline by ANP Technologies Inc, H2 2016 321 Breast Cancer - Pipeline by AntiCancer Inc, H2 2016 322 Breast Cancer - Pipeline by Antigen Express Inc, H2 2016 323 Breast Cancer - Pipeline by Antoxis Ltd, H2 2016 324 Breast Cancer - Pipeline by Aphios Corp, H2 2016 325 Breast Cancer - Pipeline by APIM Therapeutics AS, H2 2016 326 Breast Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 327 Breast Cancer - Pipeline by Aravive Biologics Inc, H2 2016 328 Breast Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 329 Breast Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 330 Breast Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 331 Breast Cancer - Pipeline by ArQule Inc, H2 2016 332 Breast Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 333 Breast Cancer - Pipeline by Arvinas Inc, H2 2016 334 Breast Cancer - Pipeline by Asana BioSciences LLC, H2 2016 335 Breast Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 336 Breast Cancer - Pipeline by AskAt Inc, H2 2016 337 Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 338 Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016 339 Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 340 Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016 341
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
